South African regulator reviewing 12 generic semaglutide applications
The filings signal that lower-cost copies of the GLP-1 could reach one of Africa's largest pharmaceutical markets once reviews conclude.
DO
By Daniel Okafor · Regulatory Correspondent
Jul 21 03:00 ETSource: Reuters
The wire
- 01South Africa's medicines regulator is assessing 12 applications for generic versions of semaglutide, according to Reuters.
- 02Generic entry would reshape pricing and supply expectations for semaglutide outside the US and Europe, a reference point for clinicians and operators tracking global GLP-1 access.
- 03Review timelines, applicants and approval outcomes were not detailed, and patent litigation could still affect when any generic reaches patients.
From the source
Read at reuters.comSouth Africa regulator reviews 12 generic semaglutide applications
